Table 2.
All interventions identified to potentially modify OHSS risk
| Interventions | Systematic review with meta-analysis |
|---|---|
| Alternative hCG protocol | ✖ |
| Aspirin | ✖ |
| Calcium infusion | ✔ |
| Carbegoline | ✔ |
| Clomiphene citrate | ✔ |
| Coasting | ✔ |
| Corifollitropin alfa | ✔ |
| Cycle cancellation | ✖ |
| Diosmin | ✔ |
| Dopaminergic agonists | ✔ |
| Dual trigger | ✖ |
| Elective cryopreservation | ✔ |
| Elective single embryo transfer (e-SET) | ✖ |
| Follitropin delta | ✖ |
| FSH dose decrease | ✖ |
| Glucocorticoid | ✔ |
| GnRH analogs | ✔ |
| Inositol | ✖ |
| Insulin sensitizing drugs | ✖ |
| In vitro maturation of oocytes | ✔ |
| Intensified luteal phase support with hCG | ✖ |
| Intensified luteal phase support: GnRH agonist | ✔ |
| Ketoconazole | ✖ |
| Kisspeptin | ✖ |
| Letrozole | ✔ |
| LH addition | ✔ |
| Luteal GnRH antagonist administration | ✖ |
| Luteal phase support / GnRH agonist | ✔ |
| Luteal phase support / hCG | ✔ |
| Luteal phase support / progesterone | ✔ |
| Melatonin | ✔ |
| Metformin | ✔ |
| Mild ovarian stimulation | ✔ |
| Monitoring and surveillance | ✔ |
| Natural IVF cycles | ✔ |
| Oral contraceptives | ✔ |
| Ovarian drilling | ✔ |
| Personalization | ✔ |
| Predictive models | ✔ |
| Progestin-primed ovarian stimulation | ✔ |
| Triggering / hCG dose | ✖ |
| Triggering / GnRH agonist | ✔ |
| Triggering / r-hLH | ✔ |
| Triggering / hCG type | ✔ |
| Gonadotropins | ✔ |
| Vitamin D | ✖ |
| Volume expanders / albumin | ✔ |
| Volume expanders / hydroxyethyl starch | ✔ |